Sanofi Global Health, part of French healthcare company Sanofi S.A. (Euronext Paris:SAN), announced on Monday the launch of a new non-profit brand of standard of care medicines produced by Sanofi.

The Impact brand covers 30 products including insulin, glibenclamide and oxaliplatin, with Sanofi Global Health providing secure, non-profit distribution of these medicines to at-risk populations in 40 lower-income countries.

Considered essential by the World Health Organization, the medicines cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.

The company also announced the establishment of an Impact fund to support startup companies and other innovators that can deliver scalable solutions for sustainable healthcare in underserved regions.

Sanofi Global Health is a non-profit unit within Sanofi aiming to increase access to healthcare through the distribution of medicines as well as the building and bolstering of local healthcare systems in countries with among the lowest per capita GDP.